Latest posts by Lancet Global Health (see all)
- [Articles] Effect of Ebola virus disease on maternal and child health services in Guinea: a… - Feb. 23, 2017
- [Comment] The end of the Ebola virus disease epidemic: has the work just begun? - Feb. 23, 2017
- [Articles] Levels and trends in contraceptive prevalence, unmet need, and demand for family… - Feb. 19, 2017
- [Articles] Community resource centres to improve the health of women and children in informal… - Feb. 19, 2017
The recent devastating outbreak of Ebola virus disease led to the accelerated development of multiple candidate vaccines against this virus, with at least eight entering clinical trials in 2014–16.1 Direct evidence of 100% effectiveness against disease has been demonstrated for VSV-EBOV, a vaccine based on a replicating vesicular stomatitis virus genetically modified to express Ebola virus glycoprotein.2 This vaccine has been granted Breakthrough Therapy Designation status by the US Food and Drug Administration and PRIME status by the European Medicines Agency, and its single-dose regimen and proof of effectiveness from 10 days post-immunisation make it an attractive candidate for use in a responsive campaign (whether it be through ring immunisation around identified cases or as a whole-population intervention).